603676 卫信康
交易中 10-27 09:54:48
资讯
新帖
简况
卫信康（603676）10月26日主力资金净卖出26.46万元
证券之星 · 10-26 15:25
卫信康（603676）10月26日主力资金净卖出26.46万元
卫信康(603676.SH)子公司获得注射用水溶性维生素药品注册证书
智通财经 · 09-10
卫信康(603676.SH)子公司获得注射用水溶性维生素药品注册证书
卫信康：9月4日召开业绩说明会，投资者参与
证券之星 · 09-07
卫信康：9月4日召开业绩说明会，投资者参与
卫信康最新公告：子公司获门冬氨酸钾注射液补充申请批准通知书
证券之星 · 08-31
卫信康最新公告：子公司获门冬氨酸钾注射液补充申请批准通知书
每周股票复盘：卫信康（603676）股东户数降9.43%
证券之星 · 08-30
每周股票复盘：卫信康（603676）股东户数降9.43%
卫信康（603676）2026年中报简析：净利润同比下降21.81%
证券之星 · 08-29
卫信康（603676）2026年中报简析：净利润同比下降21.81%
股市必读：卫信康新发布《西藏卫信康医药股份有限公司2026年半年度报告摘要》
证券之星 · 08-28
股市必读：卫信康新发布《西藏卫信康医药股份有限公司2026年半年度报告摘要》
图解卫信康中报：第二季度单季净利润同比下降24.08%
证券之星 · 08-28
图解卫信康中报：第二季度单季净利润同比下降24.08%
卫信康（603676）披露2026年半年度报告及“提质增效重回报”专项行动半年度评估报告，8月27日股价上涨0.11%
证券之星 · 08-27
卫信康（603676）披露2026年半年度报告及“提质增效重回报”专项行动半年度评估报告，8月27日股价上涨0.11%
卫信康：2026年半年度营业收入为584287350.52元
证券日报 · 08-27
卫信康：2026年半年度营业收入为584287350.52元
每周股票复盘：卫信康（603676）子公司获注射用多种维生素（12）注册证
证券之星 · 08-09
每周股票复盘：卫信康（603676）子公司获注射用多种维生素（12）注册证
卫信康（603676）披露子公司获得注射用多种维生素（12）药品注册证书，8月7日股价上涨2.02%
证券之星 · 08-07
卫信康（603676）披露子公司获得注射用多种维生素（12）药品注册证书，8月7日股价上涨2.02%
股市必读：卫信康新发布《西藏卫信康医药股份有限公司参与认购私募基金份额的公告》
证券之星 · 08-05
股市必读：卫信康新发布《西藏卫信康医药股份有限公司参与认购私募基金份额的公告》
股市必读：卫信康新发布《西藏卫信康医药股份有限公司参与认购私募基金份额的公告》
证券之星 · 08-04
股市必读：卫信康新发布《西藏卫信康医药股份有限公司参与认购私募基金份额的公告》
每周股票复盘：卫信康（603676）独占许可协议终止不影响主业
证券之星 · 07-19
每周股票复盘：卫信康（603676）独占许可协议终止不影响主业
卫信康（603676）披露独占许可协议终止公告，7月17日股价下跌3.75%
证券之星 · 07-17
卫信康（603676）披露独占许可协议终止公告，7月17日股价下跌3.75%
卫信康最新公告：终止对乙酰氨基酚布洛芬注射液独占许可协议
证券之星 · 07-17
卫信康最新公告：终止对乙酰氨基酚布洛芬注射液独占许可协议
每周股票复盘：卫信康（603676）子公司获复合磷酸氢钾注射液注册证
证券之星 · 07-12
每周股票复盘：卫信康（603676）子公司获复合磷酸氢钾注射液注册证
卫信康最新公告：复合磷酸氢钾注射液获药品注册证书
证券之星 · 07-10
卫信康最新公告：复合磷酸氢钾注射液获药品注册证书
卫信康（603676）披露2025年年度权益分派实施公告，6月22日股价下跌0.69%
证券之星 · 06-22
卫信康（603676）披露2025年年度权益分派实施公告，6月22日股价下跌0.69%
加载更多
公司概况
公司名称：
西藏卫信康医药股份有限公司
所属行业：
医药制造业
上市日期：
2017-07-21
主营业务：
西藏卫信康医药股份有限公司的主营业务是化学药品制剂及其原料药的研发、生产、销售。公司的主要产品是注射用多种维生素、多种微量元素注射液、小儿多种维生素注射液。
发行价格：
5.53
{"stockData":{"symbol":"603676","market":"SH","secType":"STK","nameCN":"卫信康","latestPrice":8.68,"timestamp":1793066088000,"preClose":8.77,"halted":0,"volume":556500,"delay":0,"changeRate":-0.0103,"floatShares":434999999,"shares":434999999,"eps":0.4436,"marketStatus":"交易中","change":-0.09,"latestTime":"10-27 09:54:48","open":8.91,"high":8.91,"low":8.66,"amount":4879900,"amplitude":0.0285,"askPrice":8.68,"askSize":14,"bidPrice":8.67,"bidSize":19,"shortable":0,"etf":0,"ttmEps":0.4436,"tradingStatus":2,"nextMarketStatus":{"tag":"午间休市","tradingStatus":4,"beginTime":1793071800000},"marketStatusCode":2,"adr":0,"adjPreClose":8.77,"symbolType":"stock","openAndCloseTimeList":[[1793064600000,1793071800000],[1793077200000,1793084400000]],"highLimit":9.65,"lowLimit":7.89,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":435161500,"isCdr":false,"pbRate":2.48,"roa":"--","peRate":19.567178,"roe":"9.31%","epsLYR":0.54,"committee":0.312796,"marketValue":3777000000,"turnoverRate":0.0013,"status":1,"floatMarketCap":3777000000},"requestUrl":"/m/hq/s/603676/","defaultTab":"news","newsList":[{"id":"2678157534","title":"卫信康（603676）10月26日主力资金净卖出26.46万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2678157534","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2678157534?lang=zh_cn&edition=full","pubTime":"2026-10-26 15:25","pubTimestamp":1792999517,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2026年10月26日收盘，卫信康报收于8.77元，上涨2.21%，换手率0.55%，成交量2.41万手，成交额2107.26万元。卫信康主营业务：公司以化学药品制剂及其原料药的研发、生产、销售为主营业务,在复合维生素类、微量元素类、电解质类等领域具有较强竞争力。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102600014653.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0191","603676","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666056376","title":"卫信康(603676.SH)子公司获得注射用水溶性维生素药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2666056376","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2666056376?lang=zh_cn&edition=full","pubTime":"2026-09-10 15:37","pubTimestamp":1789025830,"startTime":"0","endTime":"0","summary":"智通财经APP讯，卫信康(603676.SH)发布公告，近日，公司全资子公司内蒙古白医制药股份有限公司收到国家药品监督管理局核准签发的注射用水溶性维生素《药品注册证书》。该药品系肠外营养不可缺少的组成部分之一，用以满足成人和儿童每日对水溶性维生素的生理需要。此次获得《药品注册证书》视同通过一致性评价。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1494365.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"卫信康(603676.SH)子公司获得注射用水溶性维生素药品注册证书","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0191","603676","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665739154","title":"卫信康：9月4日召开业绩说明会，投资者参与","url":"https://stock-news.laohu8.com/highlight/detail?id=2665739154","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665739154?lang=zh_cn&edition=full","pubTime":"2026-09-07 13:36","pubTimestamp":1788759380,"startTime":"0","endTime":"0","summary":"证券之星消息，2026年9月4日卫信康发布公告称公司于2026年9月4日召开业绩说明会。我谨代表公司对长期关注和支持卫信康的广大投资者表示诚挚的谢意，感谢各位投资者的积极参与和提出的宝贵意见，公司将认真思考和研究，在未来的企业经营中予以关注和借鉴，以更好的业绩报广大投资者。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090700013234.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603676","BK0239","BK0191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663079482","title":"卫信康最新公告：子公司获门冬氨酸钾注射液补充申请批准通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2663079482","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663079482?lang=zh_cn&edition=full","pubTime":"2026-08-31 17:37","pubTimestamp":1788169028,"startTime":"0","endTime":"0","summary":"卫信康(603676.SH)公告称，公司全资子公司洋浦京泰收到国家药监局核准签发的门冬氨酸钾注射液《药品补充申请批准通知书》，批准增加20ml规格，视同通过一致性评价。该药品为电解质补充药，用于治疗低钾血症。截至2026年7月末，累计研发投入121.84万元。2025年该药品国内公立医院终端销售金额为4.12亿元。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026083100024178.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","603676","BK0191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663135045","title":"每周股票复盘：卫信康（603676）股东户数降9.43%","url":"https://stock-news.laohu8.com/highlight/detail?id=2663135045","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663135045?lang=zh_cn&edition=full","pubTime":"2026-08-30 10:09","pubTimestamp":1788055748,"startTime":"0","endTime":"0","summary":"截至2026年8月28日收盘，卫信康报收于9.23元，较上周的9.33元下跌1.07%。本周，卫信康8月26日盘中最高价报9.52元。股本股东变化截至2026年6月30日，卫信康股东户数为1.42万户，较3月31日减少1480户，减幅9.43%。业绩披露要点卫信康2026年中报显示，上半年主营收入5.84亿元，同比下降0.32%；归母净利润1.43亿元，同比下降21.81%；扣非净利润1.03亿元，同比下降24.42%。前十大股东中，西藏卫信康企业管理有限公司持股47.17%，张勇持股12.27%，钟丽娟持股8.27%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026083000004788.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0191","BK0239","603676"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663016501","title":"卫信康（603676）2026年中报简析：净利润同比下降21.81%","url":"https://stock-news.laohu8.com/highlight/detail?id=2663016501","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663016501?lang=zh_cn&edition=full","pubTime":"2026-08-29 06:11","pubTimestamp":1787955091,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理，近期卫信康发布2026年中报。根据财报显示，卫信康净利润同比下降21.81%。截至本报告期末，公司营业总收入5.84亿元，同比下降0.32%，归母净利润1.43亿元，同比下降21.81%。按单季度数据看，第二季度营业总收入2.62亿元，同比下降9.72%，第二季度归母净利润7459.1万元，同比下降24.08%。去年的净利率为20.5%，算上全部成本后，公司产品或服务的附加值高。本文数据来源于卫信康2026年中报，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082900010677.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603676"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662037219","title":"股市必读：卫信康新发布《西藏卫信康医药股份有限公司2026年半年度报告摘要》","url":"https://stock-news.laohu8.com/highlight/detail?id=2662037219","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662037219?lang=zh_cn&edition=full","pubTime":"2026-08-28 09:29","pubTimestamp":1787880599,"startTime":"0","endTime":"0","summary":"公司公告汇总西藏卫信康医药股份有限公司2026年半年度报告摘要截至2026年6月30日，公司总资产1,964,655,715.41元，较上年度末增长5.24%；归属于上市公司股东的净资产1,540,807,617.81元，较上年度末增长4.36%。西藏卫信康医药股份有限公司关于召开2026年半年度业绩说明会的公告公司定于2026年9月4日15:00–16:00通过上证路演中心以网络互动方式召开2026年半年度业绩说明会。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082800017047.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1515","BK1161","09939","603676","BK0239","BK0191","BK1574","159938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662486082","title":"图解卫信康中报：第二季度单季净利润同比下降24.08%","url":"https://stock-news.laohu8.com/highlight/detail?id=2662486082","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662486082?lang=zh_cn&edition=full","pubTime":"2026-08-28 01:34","pubTimestamp":1787852084,"startTime":"0","endTime":"0","summary":"证券之星消息，卫信康2026年中报显示，上半年度公司主营收入5.84亿元，同比下降0.32%；归母净利润1.43亿元，同比下降21.81%；扣非净利润1.03亿元，同比下降24.42%；其中2026年第二季度，公司单季度主营收入2.62亿元，同比下降9.72%；单季度归母净利润7459.1万元，同比下降24.08%；单季度扣非净利润3548.81万元，同比下降43.23%；负债率21.57%，投资收益591.39万元，财务费用-29.02万元，毛利率59.13%。财报数据概要请见下图:本文数据来源于卫信康2026年中报，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082800004364.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603676"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662212086","title":"卫信康（603676）披露2026年半年度报告及“提质增效重回报”专项行动半年度评估报告，8月27日股价上涨0.11%","url":"https://stock-news.laohu8.com/highlight/detail?id=2662212086","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662212086?lang=zh_cn&edition=full","pubTime":"2026-08-27 22:42","pubTimestamp":1787841761,"startTime":"0","endTime":"0","summary":"截至2026年8月27日收盘，卫信康报收于9.36元，较前一交易日上涨0.11%，最新总市值为40.73亿元。该股当日开盘9.35元，最高9.46元，最低9.3元，成交额达1420.87万元，换手率为0.35%。近日，西藏卫信康医药股份有限公司召开第四届董事会第六次会议，审议通过《2026年半年度报告》和《关于2026年度“提质增效重回报”专项行动方案的半年度评估报告》。会议应出席董事8名，实际出席8名，表决结果均为赞成8票、反对0票、弃权0票。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082700056551.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0191","603676","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662702177","title":"卫信康：2026年半年度营业收入为584287350.52元","url":"https://stock-news.laohu8.com/highlight/detail?id=2662702177","media":"证券日报 ","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662702177?lang=zh_cn&edition=full","pubTime":"2026-08-27 19:25","pubTimestamp":1787829900,"startTime":"0","endTime":"0","summary":"8月27日，卫信康发布2026年半年度报告摘要称，公司2026年半年度实现营业收入584，287，350.52元，同比下降0.32%；归属于上市公司股东的净利润为142，930，218.81元，同比下降21.81%。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/cn/2026-08-27/doc-inipuiyu0707164.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2026-08-27/doc-inipuiyu0707164.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["603676"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658675464","title":"每周股票复盘：卫信康（603676）子公司获注射用多种维生素（12）注册证","url":"https://stock-news.laohu8.com/highlight/detail?id=2658675464","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658675464?lang=zh_cn&edition=full","pubTime":"2026-08-09 03:13","pubTimestamp":1786216391,"startTime":"0","endTime":"0","summary":"截至2026年8月7日收盘，卫信康报收于9.08元，较上周的8.8元上涨3.18%。本周关注点来自公司公告汇总：子公司内蒙古白医制药获注射用多种维生素药品注册证书。西藏卫信康医药股份有限公司全资子公司内蒙古白医制药股份有限公司近日收到国家药品监督管理局核准签发的注射用多种维生素《药品注册证书》，该药品为化学药品4类，适用于需静脉补充维生素的成人及11岁以上儿童患者。截至2026年7月末，累计研发投入1131.39万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080900001096.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603676","BK0239","BK0191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657423316","title":"卫信康（603676）披露子公司获得注射用多种维生素（12）药品注册证书，8月7日股价上涨2.02%","url":"https://stock-news.laohu8.com/highlight/detail?id=2657423316","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657423316?lang=zh_cn&edition=full","pubTime":"2026-08-07 22:41","pubTimestamp":1786113674,"startTime":"0","endTime":"0","summary":"截至2026年8月7日收盘，卫信康报收于9.08元，较前一交易日上涨2.02%，最新总市值为39.51亿元。西藏卫信康医药股份有限公司近日披露，其全资子公司内蒙古白医制药股份有限公司收到国家药品监督管理局核准签发的注射用多种维生素《药品注册证书》。截至目前，国内共有4家企业包括白医制药获批该药品上市。2025年该药品在公立医疗机构终端销售额为16.01亿元。截至2026年7月末，累计研发投入1131.39万元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080700041583.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603676","BK0239","BK0191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657565447","title":"股市必读：卫信康新发布《西藏卫信康医药股份有限公司参与认购私募基金份额的公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2657565447","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657565447?lang=zh_cn&edition=full","pubTime":"2026-08-05 03:00","pubTimestamp":1785870042,"startTime":"0","endTime":"0","summary":"截至2026年8月4日收盘，卫信康报收于8.81元，下跌0.56%，换手率0.53%，成交量2.3万手，成交额2031.99万元。公司公告汇总西藏卫信康医药股份有限公司参与认购私募基金份额的公告西藏卫信康医药股份有限公司作为有限合伙人，以自有资金出资2,000万元认缴上海齐济致胜创业投资合伙企业份额，占基金已募集总额的2.20%。公司承担的风险敞口以投资额为限，无保本及最低收益承诺。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080500002434.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","09939","BK1574","BK0191","603676","BK1161","159938","BK1515"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656830696","title":"股市必读：卫信康新发布《西藏卫信康医药股份有限公司参与认购私募基金份额的公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2656830696","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2656830696?lang=zh_cn&edition=full","pubTime":"2026-08-04 02:29","pubTimestamp":1785781752,"startTime":"0","endTime":"0","summary":"截至2026年8月3日收盘，卫信康报收于8.86元，上涨0.68%，换手率0.43%，成交量1.85万手，成交额1632.1万元。公司公告汇总：卫信康以自有资金2,000万元认缴上海齐济致胜创业投资基金份额，占比2.20%，投资方向为全球前沿医疗及生命科学技术领域。公司公告汇总西藏卫信康医药股份有限公司参与认购私募基金份额的公告西藏卫信康医药股份有限公司作为有限合伙人，以自有资金出资2,000万元认缴上海齐济致胜创业投资合伙企业份额，占基金已募集总额的2.20%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080400001788.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1161","BK0191","BK1574","603676","159938","BK1515","BK0239","09939"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652525837","title":"每周股票复盘：卫信康（603676）独占许可协议终止不影响主业","url":"https://stock-news.laohu8.com/highlight/detail?id=2652525837","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2652525837?lang=zh_cn&edition=full","pubTime":"2026-07-19 03:33","pubTimestamp":1784403189,"startTime":"0","endTime":"0","summary":"截至2026年7月17日收盘，卫信康报收于8.99元，较上周的8.76元上涨2.63%。本周，卫信康7月16日盘中最高价报9.46元。本周关注点公司公告汇总：独占许可协议终止，合作产品处前期阶段 公司公告汇总西藏卫信康医药股份有限公司全资子公司中卫诚康与AFT公司签署《独占许可协议》，获对乙酰氨基酚布洛芬注射液中国大陆地区独占许可。本次终止不会对公司生产经营、核心业务及财务状况产生重大影响。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071900001289.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0191","603676"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652029289","title":"卫信康（603676）披露独占许可协议终止公告，7月17日股价下跌3.75%","url":"https://stock-news.laohu8.com/highlight/detail?id=2652029289","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2652029289?lang=zh_cn&edition=full","pubTime":"2026-07-17 22:45","pubTimestamp":1784299515,"startTime":"0","endTime":"0","summary":"截至2026年7月17日收盘，卫信康报收于8.99元，较前一交易日下跌3.75%，最新总市值为39.12亿元。近日，西藏卫信康医药股份有限公司发布《关于独占许可协议终止的公告》。公告显示，2024年9月27日，公司全资子公司中卫诚康与AFT公司签署《独占许可协议》，获得对乙酰氨基酚布洛芬注射液在中国大陆地区的独占许可。合作产品处于前期开发阶段，中卫诚康将在3个工作日内销毁AFT公司提供的全部资料并出具证明，AFT公司退还已支付的30万美元首付款。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071700045209.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0191","603676"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652940925","title":"卫信康最新公告：终止对乙酰氨基酚布洛芬注射液独占许可协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2652940925","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2652940925?lang=zh_cn&edition=full","pubTime":"2026-07-17 17:18","pubTimestamp":1784279907,"startTime":"0","endTime":"0","summary":"卫信康(603676.SH)公告称，公司全资子公司中卫诚康与AFT公司签署的《独占许可协议》终止。因相关行业政策及市场环境变化，为合理配置资源，双方协商一致终止协议。AFT公司将退还已支付的首付款30万美元。本次终止不会对公司生产经营及财务状况产生重大影响。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071700031621.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0191","BK0239","603676"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650152843","title":"每周股票复盘：卫信康（603676）子公司获复合磷酸氢钾注射液注册证","url":"https://stock-news.laohu8.com/highlight/detail?id=2650152843","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2650152843?lang=zh_cn&edition=full","pubTime":"2026-07-12 03:19","pubTimestamp":1783797548,"startTime":"0","endTime":"0","summary":"截至2026年7月10日收盘，卫信康报收于8.76元，较上周的8.81元下跌0.57%。本周，卫信康7月6日盘中最高价报9.12元。本周关注点公司公告汇总：全资子公司获复合磷酸氢钾注射液药品注册证书，视同通过一致性评价。公司公告汇总西藏卫信康医药股份有限公司全资子公司内蒙古白医制药股份有限公司近日收到国家药品监督管理局核准签发的复合磷酸氢钾注射液《药品注册证书》，批准注册并视同通过一致性评价。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071200001258.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603676","BK0239","BK0191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650186561","title":"卫信康最新公告：复合磷酸氢钾注射液获药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2650186561","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2650186561?lang=zh_cn&edition=full","pubTime":"2026-07-10 17:15","pubTimestamp":1783674912,"startTime":"0","endTime":"0","summary":"卫信康(603676.SH)公告称，全资子公司白医制药收到国家药监局核准签发的复合磷酸氢钾注射液药品注册证书。复合磷酸氢钾注射液在美国最早于1983年获批，用于纠正低磷血症和肠外营养支持，目前已在加拿大等国上市。原研参比制剂未在中国上市。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071000030713.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603676","BK0191","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645075354","title":"卫信康（603676）披露2025年年度权益分派实施公告，6月22日股价下跌0.69%","url":"https://stock-news.laohu8.com/highlight/detail?id=2645075354","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2645075354?lang=zh_cn&edition=full","pubTime":"2026-06-22 22:58","pubTimestamp":1782140296,"startTime":"0","endTime":"0","summary":"截至2026年6月22日收盘，卫信康报收于8.58元，较前一交易日下跌0.69%，最新总市值为37.34亿元。该股当日开盘8.64元，最高8.71元，最低8.27元，成交额达2015.43万元，换手率为0.55%。近日，西藏卫信康医药股份有限公司发布《2025年年度权益分派实施公告》：每股现金红利0.18元（含税），股权登记日为2026年6月26日，除权（息）日和现金红利发放日均为2026年6月29日。根据持股期限不同，自然人股东股息红利所得税实行差别化税率。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062200039448.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0191","603676"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1793066099232,"stockEarnings":[{"period":"1week","weight":0},{"period":"1month","weight":-0.009},{"period":"3month","weight":0.0306},{"period":"6month","weight":-0.1543},{"period":"1year","weight":-0.2363},{"period":"ytd","weight":-0.1479}],"compareEarnings":[{"period":"1week","weight":-0.009},{"period":"1month","weight":-0.0491},{"period":"3month","weight":-0.0304},{"period":"6month","weight":-0.0998},{"period":"1year","weight":-0.064},{"period":"ytd","weight":-0.0684}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"西藏卫信康医药股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"14208人(较上一季度减少9.43%)","perCapita":"30627股","listingDate":"2017-07-21","address":"西藏自治区拉萨市堆龙德庆区经济技术开发区B区园区南路5号工业中心4号楼3层","registeredCapital":"43516万元","survey":" 西藏卫信康医药股份有限公司的主营业务是化学药品制剂及其原料药的研发、生产、销售。公司的主要产品是注射用多种维生素、多种微量元素注射液、小儿多种维生素注射液。","listedPrice":5.53},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.52.0","shortVersion":"4.52.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"卫信康(603676)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供卫信康(603676)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"卫信康,603676,卫信康股票,卫信康股票老虎,卫信康股票老虎国际,卫信康行情,卫信康股票行情,卫信康股价,卫信康股市,卫信康股票价格,卫信康股票交易,卫信康股票购买,卫信康股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"卫信康(603676)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供卫信康(603676)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}